低剂量螺内酯对中度慢性肾脏病心血管结局的影响:一项随机对照试验
这项前瞻性、随机、开放、盲法终点试验在1434例来自英格兰初级保健的3b期慢性肾脏病患者中评估25 mg螺内酯加常规治疗与单用常规治疗的心血管结局。中位随访3年,主要终点在螺内酯组677例中发生113例(16.7%),常规治疗组695例中发生111例(16.0%),两组无显著差异(HR=1.05,95%CI 0.81-1.37)。螺内酯组三分之二参与者在6个月内停药,主要因符合预设安全停药标准。
要点
- 在3b期慢性肾脏病患者中,25 mg螺内酯未显著降低心血管结局(HR=1.05,95%CI 0.81-1.37)。
- 螺内酯组677例中113例(16.7%)发生主要终点,常规治疗组695例中111例(16.0%)。
- 螺内酯组三分之二参与者在6个月内停药,最常见原因为符合预设eGFR下降停药标准(n=239,35.4%)。
核心结论
- 螺内酯因安全性问题频繁停药,且无证据表明其降低3b期慢性肾脏病患者的心血管结局。
- 作者认为,若无其他明确治疗指征,3b期慢性肾脏病患者不应使用螺内酯。
研究设计与样本
- 前瞻性、随机、开放、盲法终点试验,纳入1434例来自英格兰初级保健的3b期慢性肾脏病老年社区队列参与者(平均年龄74.8岁,s.d.=8.1)。
- 1372例(96%)纳入主要分析,随机分配至25 mg螺内酯加常规治疗组(677例)或单用常规治疗组(695例)。
- 主要终点为从随机化至首次发生死亡、心脏病住院、卒中、心力衰竭、短暂性脑缺血发作或外周动脉疾病,或基线不存在的所列任何疾病首次发生的时间。
- 随访3年。
主要发现
- 主要终点在螺内酯组677例中发生113例(16.7%),常规治疗组695例中发生111例(16.0%),两组无显著差异(HR=1.05,95%CI 0.81-1.37)。
- 螺内酯组三分之二参与者在6个月内停药,主要因符合预设安全停药标准。
- 停用螺内酯最常见原因为估算肾小球滤过率下降符合预设停药标准(n=239,35.4%),其次为因治疗副作用退出(n=128,18.9%)和高钾血症(n=54,8.0%)。
临床怎么用
- 作者认为,若无其他明确治疗指征,3b期慢性肾脏病患者不应使用螺内酯。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is associated with a substantial risk of progression to end-stage renal disease and vascular events. The nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardiorenal protection for people with CKD and diabetes, but there is uncertainty if the steroidal MRA, spironolactone, provides the same protection. In this prospective, randomized, open, blinded endpoint trial, we assessed the effectiveness of 25 mg spironolactone in addition to usual care or usual care alone for reducing cardiovascular outcomes in stage 3b CKD among an older community cohort (mean age = 74.8 years and s.d. = 8.1). We recruited 1,434 adults from English primary care, of whom 1,372 (96%) were included in the primary analysis. The primary outcome was time from randomization until the first occurrence of death, hospitalization for heart disease, stroke, heart failure, transient ischemic attack or peripheral arterial disease, or first onset of any condition listed not present at baseline. Across 3 years of follow-up, the primary endpoint occurred in 113 of 677 participants randomized to spironolactone (16.7%) and 111 of 695 participants randomized to usual care (16.0%) with no significant difference between groups (hazard ratio = 1.05, 95% confidence interval: 0.81-1.37). Two-thirds of participants randomized to spironolactone stopped treatment within 6 months, predominantly because they met prespecified safety stop criteria. The most common reason for stopping spironolactone was a decrease in the estimated glomerular filtration rate that met prespecified stop criteria (n = 239, 35.4%), followed by participants being withdrawn due to treatment side effects (n = 128, 18.9%) and hyperkalemia (n = 54, 8.0%). In conclusion, we found that spironolactone was frequently discontinued due to safety concerns, with no evidence that it reduced cardiovascular outcomes in people with stage 3b CKD. Spironolactone should not be used for people with stage 3b CKD without another explicit treatment indication. ClinicalTrials.gov registration: ISRCTN44522369 .
引用
- Hobbs FDR, McManus RJ, Taylor CJ, et al. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat Med. 2024. PMID: 39349629. doi:10.1038/s41591-024-03263-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。